TGM5

Across TCGA pan-cancer cohorts, TGM5 Mutation is linked to patient survival in 11 of 34 cancer types, making it a survival-associated TGM5 data layer compared with 22 for mass-spec protein and 2 for mass-spec protein.

The strongest signal is observed in small cell lung cancer (SCLC), where higher TGM5 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated TGM5 expression acts as an unfavorable survival marker, although some lineages such as STAD and SKCM show a favorable association.

SCLC, ESCA, and UCS are the cancer types where TGM5 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SCLC	OS	Median	All	0.055	0.708	<.001	12	view →
ESCA	OS	Median	All	0.198	0.872	.003	12	view →
UCS	OS	Median	All	0.185	0.686	.034	6	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
STAD	DFS	Median	II,III,IV	1.000	0.477	.043	6	view →
LUAD	OS	Median	All	0.250	0.700	.001	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
SKCM	DFS	Median	III,IV	0.845	0.197	.013	5	view →
BLCA	DFS	Median	III,IV	0.192	0.474	.028	3	view →
LIHC	OS	Median	II,III,IV	0.239	0.715	.035	3	view →
LUSC	DFS	Median	All	0.710	0.382	.047	2	view →

Pink = unfavorable, green = favorable. Showing the 11 strongest of 11 lineages.

TGM5–SCLC (OS)

Open the SCLC breakdown →